Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Sarcoma

4238 - A Phase 2 Study of CMB305 and Atezolizumab in NY-ESO-1+ Soft Tissue Sarcoma: Interim Analysis of Immunogenicity, Tumor Control and Survival

Date

11 Sep 2017

Session

Sarcoma

Presenters

Sant Chawla

Citation

Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387

Authors

S. Chawla1, B.A. Van Tine2, S. Pollack3, K. Ganjoo4, A. Elias5, R.F. Riedel6, S. Attia7, E. Choy8, S. Okuno9, M. Agulnik10, M. von Mehren11, M. Livingston12, V. Keedy13, C. Verschraegen14, T. Philip15, C. Bohac16, H. Lu16, M. Chen16, R. Maki15

Author affiliations

  • 1 Oncology, Sarcoma Oncology Center, 90403 - Santa Monica/US
  • 2 Medical Oncology, Washington University, St Louis/US
  • 3 Medical Oncology, Fred Hutchinson Cancer Research Center, Seattle/US
  • 4 Medical Oncology, Stanford Medical Center, Palo Alto/US
  • 5 Medical Oncology, University of Colorado Cancer Center, Aurora/US
  • 6 Medical Oncology, Duke Cancer Institute, Durham/US
  • 7 Oncology, Mayo Jacksonville, Jacksonville/US
  • 8 Medical Oncology, Dana Farber Cancer Institute, Boston/US
  • 9 Medical Oncology, Mayo Clinic, 55905 - Rochester/US
  • 10 Oncology, m.agulnik@northwestern.edu, Chicago/US
  • 11 Medical Oncology, Fox Chase Cancer Center, 19111-2497 - Philadelphia/US
  • 12 Medical Oncology, Levine Cancer Institute, Charlotte/US
  • 13 Medical Oncology, Vanderbilt, Nashville/US
  • 14 Ohio State University Medical Center, James Cancer Center, Cincinnati/US
  • 15 Medical Oncology, North Shore-LIJ Health System, 11040 - New Hyde Park/US
  • 16 Clinical Development, Immune Design, South San Francisco/US
More

Resources

Abstract 4238

Background

CMB305 is an active immunotherapy designed to generate and expand anti-NY-ESO-1 immune response (IR). CMB305 consists of a dendritic cell-targeting lentiviral vector encoding NY-ESO-1 (LV305), and a boost with an NY-ESO-1 recombinant protein plus GLA-SE (G305), a TLR-4 agonist. Phase 1 studies of LV305 and CMB305 showed this approach is safe, generates IR and appears to impact survival with 81% 1-yr survival in NY-ESO-1+ sarcoma patients (pts) following LV305 treatment. We evaluated efficacy and IR for combination of CMB305 (C) and atezolizumab (A) or A alone in NY-ESO-1+ synovial sarcoma (SS) and myxoid round cell liposarcoma (MRCL).

Methods

A prospective randomized open label phase 2 study of C (LV305 Intradermal Days 0, 14, 42, 70 + G305 Intramuscular Days 28, 56, 84 then q6wk up to one year) + A (1200mg IV q3wk) vs. A alone in locally advanced or metastatic NY-ESO-1+ SS/MRCL. Primary endpoints are progression free survival (PFS) and overall survival (OS) with secondary endpoints of safety, IR, and response rate.

Results

As of December 30, 2016, 58 patients were enrolled. A prespecified interim analysis of PFS included the first 36 pts with median 7.0 mos follow up (Arm A+C: median age 47 yrs, 78% SS, 100% metastatic, 78% = >2 chemotherapy; Arm A: median age 44 yrs, 56% SS, 67% metastatic, 56% = >2 chemotherapy). Combination A+C was well tolerated. Clinical benefit was similar between arms (Arm A+C: 8/18 pts with SD, 1 pt unconfirmed PR, 6 mos PFS rate 17%; Arm A: 10/18 pts SD, 6 mos PFS rate 22%). In addition, anti-NY-ESO-1 IR seen in 10/19 (53%) pts Arm A+C vs. 3/12 (25%) pts Arm A by T Cell ELISpot, and 9/22 (41%) pts Arm A+C vs. 0% Arm A by antibody ELISA. Pts with IR had target lesion increase of 2% compared to 18% in pts without IR based on preliminary ANOVA-model based analysis. No deaths observed in pts with induced anti-NY-ESO-1 T cell IR (0/13 deaths IR+ pts vs. 5/18 deaths IR- pts).

Conclusions

In the interim analysis, Arm A+C resulted in a higher level of anti-NY-ESO-1 IR when compared to Arm A; pts with IR tend to have better target lesion control. Early data indicate that induction of anti-NY-ESO-1 IR may be associated with better survival.

Clinical trial identification

NCT02609984 First received: November 14, 2015 Last updated: February 28, 2017 Last verified: December 2016

Legal entity responsible for the study

Immune Design

Funding

Immune Design

Disclosure

S. Chawla: Board of Directors/Stock: Prana, Uptick Health, Counterpoint Biomedical. Honoraria: Amgen, Threshold, Cytrx, Pharmamar, J&J, Tracon, Morphetek. Research project: Amgen, Threshold, Cytrx, Pharmamar, J&J, Tracon, Morphotek, BMS, Etsai, Immune Design. B.A. Van Tine: Stock ownership: none Membership on Advisory Board Novartis Lilly Janseen Epizyme Karyopharm Diiachi Board of Directors none Corporate sponsored research Pfizer Merck Speakers Beuro Caris Janseen Lilly. K. Ganjoo: Compensation to author for Advisory board with both Daiichi Sanko and Novartis. R.F. Riedel: Sponsored Research/Advisory Board: AADi, Arog, Daiichi-Sankyo, Karyopharm, Lilly, Novartis, Oncternal, Plexxikon, SARC, Threshold, Tracon, Tokalas. Eisai, EMD-Serono, Ignyta, Immune Design, Janssen. Consultant: Lilly, The Oncology Consortium. S. Attia: Compensation (to Mayo Clinic) as Principal Investigator from: AB Science, Morphotek, Threshold Pharmaceuticals, Tracon Pharma, ZioPharm, CytRX, Bayer, Novartis, Daichii, Bayer, Lilly, Immune Design, Karyopharm Therapeutics, Epizyme. E. Choy: Consulting fees from Amgen, EMD Serono, Daiichi, Bayer. M. Agulnik: Advisory board: Novartis, Janssen, Eisai and Lilly. V. Keedy: Consultant Karyopharm Janssen Research funding to institution for sponsored research: Lilly, Plexxicon, CytRx, Daiichi, Threshold, Janssen, Roche, Astrazeneca, MedPacto, Immune Design, GSK. T. Philip: Consultant: Novartis. C. Bohac: Employed by Immune Design. Stock ownership with Amgen, Immune Design H. Lu: Employee of Immune Design and Stock ownership Immune Design. M. Chen: Employee of Immune Design and Stock Ownership Immune Design. R. Maki: Clinical Trial support (institution), consulting fees, travel: Immune Design. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.